Azenta Q3: Revenue Climbs 12%, but Material Weaknesses Linger and Goodwill Impairment Drags on Full-Year Results
AZTA sits 93% above its 52-week low of $15.93.
Summary
Azenta posted Q3 revenue of $161.2 million, a 12% year-over-year increase, but revealed that material weaknesses in internal controls are still outstanding. A $149.1 million goodwill impairment drove a nine-month loss, and the company finalized the sale of its B Medical Systems unit.
Key Events · Earnings and Guidance · AZTA
-
Material Weaknesses Persist
Disclosure controls were ineffective as of June 30, 2026, because two material weaknesses in internal control over financial reporting remain—one involving the cash flow statement review and the other concerning account reconciliations. A previously identified weakness in expense classification has been remediated.
-
$149.1M Goodwill Impairment
A non-cash goodwill impairment charge of $149.1 million was recorded in the nine months ended June 30, 2026, reflecting declines in the Multiomics and Sample Management Solutions reporting units.
-
$17.5M Unrecognized Tax Benefit
An additional $17.5 million unrecognized tax benefit was recorded, tied to a capital loss on a foreign subsidiary, representing a tax position that does not meet the more-likely-than-not recognition standard.
-
B Medical Systems Sale Completed
On July 1, 2026, Azenta completed the sale of its B Medical Systems business for $63.0 million, comprising $28.0 million in cash and a $35.0 million vendor loan. The loan matures in three months and carries a 6.0% interest rate.
Analysis · AZTA · Technology
While Azenta's Q3 revenue advanced 12% to $161.2 million, the company is still wrestling with material weaknesses in its internal controls over financial reporting. Two such weaknesses remain unresolved, though one tied to expense classification has been remediated. The nine-month results are heavily burdened by a non-cash goodwill impairment charge of $149.1 million, pushing the loss from continuing operations to $163.7 million. Additionally, a $17.5 million unrecognized tax benefit was disclosed, and the sale of the B Medical Systems business closed at $63 million—delivering $28 million in cash and a $35 million vendor loan. The persistence of material weaknesses raises governance concerns, while the impairment and tax benefit underscore an ongoing balance-sheet cleanup.
At the time of this filing, AZTA was trading at $30.74 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.93 to $41.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.